Verition Fund Management
KRTX

Verition Fund Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Verition Fund Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,665
Closed -$4.01M – 3040
2023
Q4 		$4.01M Buy
12,665
+10,377
+454% +$2.02M 0.03% 528
2023
Q3 		$387K Sell
2,288
-3,338
-59% -$628K ﹤0.01% 1585
2023
Q2 		$1.22M Buy
+5,626
New +$1.21M 0.02% 862
2023
Q1 		– Sell
-2,199
Closed -$432K – 2667
2022
Q4 		$432K Buy
2,199
+196
+10% +$42K 0.01% 1315
2022
Q3 		$451K Buy
2,003
+414
+26% +$83.8K 0.01% 1963
2022
Q2 		$201K Buy
+1,589
New +$183K ﹤0.01% 1950

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Verition Fund Management's KRTX Position: Q1 2024 in Review

Verition Fund Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 12,665 shares — an estimated $4.01M sold.

Verition Fund Management first reported a position in KRTX in Q2 2022 and held it in 6 quarters. The position peaked at $4.01M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Verition Fund Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Verition Fund Management sold 12,665 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.01M.
  • Verition Fund Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Verition Fund Management's Karuna Therapeutics, Inc. Common Stock position peaked at $4.01M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.